It is popular to use physical
therapy to the face skin.
对面部皮肤使用物理治疗是很受欢迎的。
Some people have to give up
therapy when the treatment costs is very high.
当治疗费用很高时，有些人不得不放弃治疗。
She hase been in
therapy for 3 months.
她已经接受了3个月的治疗。
According to the agreement, the company will spend 190 million yuan ($26.5 million) to build a new production line for Dapagliflozin and Metformin Hydrochloride, a diabetes therapy that was marketed in China last November.
根据协议，该公司将斥资1.9亿元人民币（2650万美元）建造一条新的达格列嗪和盐酸二甲双胍生产线，后者是一种糖尿病疗法，去年11月在中国上市。
Proton therapy is one of the most advanced cancer treatments nowadays.
质子治疗是目前癌症最先进的治疗方法之一。
Proton therapy is an advanced radiation treatment method for cancer.
质子治疗是癌症的一种先进的放射治疗方法。
In the last decade, there has been an exponential increase of new proton therapy facilities.
在过去的十年里，新的质子治疗设施呈指数级增长。
According to the Particle Therapy Co-Operative Group, by the end of 2022, more than 312,000 patients had been treated with proton therapy.
根据粒子治疗合作小组的数据，截至2022年底，已有超过31.2万名患者接受了质子治疗。
Cooperation between IBA and CGN Nuclear Technology Development on proton therapy is an important achievement of win-win cooperation between Belgium and China, and will benefit more cancer patients in China, IBA said.
IBA表示，IBA与中广核在质子治疗方面的合作是中比合作共赢的重要成果，将惠及更多中国癌症患者。
IBA is a notable player in particle accelerator technology and a provider of proton therapy products and technology.
IBA是粒子加速器技术领域的著名参与者，也是质子治疗产品和技术的提供商。
Its products are widely used in about 75 proton therapy centers around the world and have treated more than 120,000 patients.
其产品广泛应用于全球约75个质子治疗中心，已治疗超过120000名患者。
In August 2020, IBA and CGNNT entered into a strategic partnership on proton therapy.
2020年8月，IBA和CGNNT在质子治疗方面建立了战略合作伙伴关系。
Based on the cooperation, CGNNT has introduced IBA to multiroom proton therapy technology and realized the localization and autonomy of proton therapy products through digestion, absorption and re-innovation.
基于合作，CGNNT将IBA引入多室质子治疗技术，通过消化、吸收和再创新，实现了质子治疗产品的本地化和自主化。
The companies are now jointly installing proton therapy sites in Shenzhen and Chengdu, which are estimated to begin clinical treatment in 2025.
两家公司目前正在深圳和成都联合安装质子治疗点，预计将于2025年开始临床治疗。
Both parties believe and anticipate the comprehensive cooperation will accelerate the application of proton therapy, drive coordinated development of the proton therapy industry chain, reduce equipment costs and benefit more cancer patients in China and around the world.
双方相信并期待此次全面合作将加速质子治疗的应用，推动质子治疗产业链协调发展，降低设备成本，惠及中国及世界更多癌症患者。
BEIJING — A group of Chinese researchers has created a gene target therapy drug for amyotrophic lateral sclerosis, or ALS.
北京——一组中国研究人员开发了一种针对肌萎缩侧索硬化症（ALS）的基因靶向治疗药物。
SineuGene Therapeutics, a biopharmaceutical company, successfully completed a clinical drug delivery attempt of adeno-associated virus vector gene therapy for ALS.
生物制药公司SineuGene Therapeutics成功完成了腺相关病毒载体基因治疗ALS的临床药物递送尝试。
Cell and gene therapy is a potential future business for Beijing.
细胞和基因治疗是北京未来的一项潜在业务。
Following the approval of a new indication, Toripalimab, China's first homegrown PD-1 anti-cancer treatment, has become the first approved perioperative therapy for lung cancer in China and the second worldwide, its developer Shanghai Junshi Biosciences Co Ltd said.
开发商上海君实生物科技有限公司表示，在新适应症获得批准后，中国首个国产PD-1抗癌治疗药物托里帕利单抗已成为中国首个获得批准的癌症围手术期治疗方法，也是全球第二个获得批准。
The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.
该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。
Radical surgery in combination with chemotherapy is a way to prevent recurrence, but chemotherapy alone, as preoperative neoadjuvant or postoperative adjuvant therapy, has limited clinical benefits and can only raise patients' 5-year survival rate by approximately 5 percent.
根治性手术联合化疗是预防复发的一种方法，但单独化疗作为术前新辅助或术后辅助治疗，临床益处有限，只能将患者的5年生存率提高约5%。
The first six indications, including as a treatment for unresectable or metastatic melanoma after the failure of standard systemic therapy, have been included in the 2023 edition of the national reimbursement drug list.
前六个适应症，包括标准全身治疗失败后不可切除或转移性黑色素瘤的治疗，已被列入2023年版的国家报销药物清单。
Multinational pharmaceutical company Novartis said on Friday it would invest more than 600 million yuan ($84 million) in a new radiopharmaceutical production site to accelerate the introduction of innovative radioligand therapy that will benefit cancer patients in China.
跨国制药公司诺华周五表示，将投资超过6亿元人民币（8400万美元）建设一个新的放射性药物生产基地，以加快引入创新的放射性配体疗法，使中国癌症患者受益。
"We look forward to establishing the new production site as a crucial step toward accelerating the introduction of radioligand therapy in China, contributing to the development of the nuclear medical industry and the clinical utilization of related therapies," she said.
她说：“我们期待着建立新的生产基地，这是加快在中国引入放射性配体疗法的关键一步，有助于核医疗行业的发展和相关疗法的临床应用。”。
Radioligand therapy is a new generation of targeted therapeutic radiopharmaceuticals that can be selectively targeted to bind to the corresponding diseased tissues, using radiation energy to kill them.
放射配体疗法是新一代靶向治疗性放射性药物，可以选择性靶向结合相应的病变组织，使用辐射能量杀死它们。
An innovative medicine for Novartis' targeted radioligand therapy has been approved in the United States and the European Union to treat a type of prostate cancer.
一种用于诺华靶向放射性配体治疗的创新药物已在美国和欧盟获得批准，用于治疗一种类型的前列腺癌症。
A multicenter clinical study on the therapy is underway in China.
一项关于该疗法的多中心临床研究正在中国进行。
The NMPA approval of the therapy, which is the first approved medicine with an IgAN indication in China, marks a new milestone in IgAN treatment in the country, said the company.
该公司表示，NMPA批准该疗法是中国首个批准的IgAN适应症药物，标志着中国IgAN治疗的一个新里程碑。
"While actively preparing for the commercial launch of Nefecon and bringing this first-in-disease therapy to patients in China as soon as possible, the company will continue to develop other innovative drug candidates in renal and auto-immune diseases to benefit more Chinese and Asian patients," he said.
他说：“在积极准备Nefecon的商业上市并尽快将这一首个疾病治疗推向中国患者的同时，该公司将继续开发其他肾脏和自身免疫疾病的创新候选药物，使更多中国和亚洲患者受益。”。
Biopharmaceutical company Teva spotlights two products that are making China debuts: an innovative migraine therapy, Fremanezumab, and a consumer healthcare product, Sudocrem®.
生物制药公司Teva重点介绍了两种在中国首次亮相的产品：一种是创新的偏头痛疗法Fremanezumab，另一种是消费类医疗保健产品Sudocrem®。
An innovative long-acting HIV therapy by US-based biopharmaceutical company Gilead Sciences will make its China debut at this year's CIIE.
美国生物制药公司吉利德科学公司的一种创新的长效HIV疗法将在今年的CIIE上首次在中国亮相。
Takeda announced an exclusive agreement last week with Shanghai-based Belief BioMed Inc to accelerate the commercialization of an innovative gene therapy for hemophilia type B in the Chinese market.
武田上周宣布与总部位于上海的Believe BioMed Inc达成独家协议，以加快B型血友病创新基因疗法在中国市场的商业化。
He mentioned Inclisiran, an innovative therapy used to lower cholesterol, as an example.
他提到了用于降低胆固醇的创新疗法Incisiran作为一个例子。
"Regarding the future of the valve sector, we look forward to introducing more innovative biological valve products, such as the RESILIA series of transcatheter and surgical biological valve products, into China, and laying out the sector of transcatheter therapy for mitral and tricuspid valves," said Ye.
叶说：“关于瓣膜行业的未来，我们期待着将更多创新的生物瓣膜产品引入中国，如RESILIA系列经导管和外科生物瓣膜产品，并布局二尖瓣和三尖瓣的经导管治疗领域。”。
The aim, Shi said, is to localize the production of the injectant, to ensure high-quality supply of the innovative compound therapy that combines two complementary ingredients for simple injection once a day.
施说，其目的是实现注射剂的本地化生产，以确保创新的复合疗法的高质量供应，该疗法结合了两种互补成分，每天注射一次。
For example, in a clinical study regarding the first inhalation therapy that only needs to be taken once daily to treat chronic obstructive pulmonary disease (COPD), which was marketed in China in 2019, Chinese patients were recruited at the same time research kicked off globally.
例如，在2019年在中国上市的第一种治疗慢性阻塞性肺病（COPD）的吸入疗法的临床研究中，在全球研究启动的同时，招募了中国患者。
China's inhalation therapy market approval came two years after it obtained market approval globally, far more rapidly than the situation in previous years.
中国的吸入疗法在获得全球市场批准两年后获得市场批准，速度远超前几年。
Nirsevimab, the world's first broadly protective option against respiratory syncytial virus (RSV) designed for infants, has been granted the breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration.
Nirsevimab是世界上第一种针对婴儿设计的呼吸道合胞病毒（RSV）的广泛保护性选择，已被国家医疗产品管理局药物评估中心授予突破性治疗指定。
They said the joint venture will help increase the adoption of radiation therapy in China's lower-tier cities, where around 70 percent of the population resides.
他们说，这家合资企业将有助于在中国约70%的人口居住的低线城市增加放射治疗的采用。
The collaboration with Sinopharm will help ensure that people in China will have access to the same high-quality precision radiation therapy, regardless of where they live, said Gong Anming, Elekta's executive vice-president.
医科达执行副总裁龚安明表示，与国药集团的合作将有助于确保中国人民无论住在哪里，都能获得同样高质量的精确放射治疗。
In terms of research and development in the company's rare diseases therapy catalog, Hu said China and the rest of the world are developing at the same time.
胡说，在公司罕见病治疗目录的研发方面，中国和世界其他地区正在同时发展。
In November, China approved the first rare disease therapy from AstraZeneca, bringing innovative treatment options to paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome, two diseases related to kidney and blood vessel malfunctions in adults and children.
11月，中国批准了阿斯利康的首个罕见病疗法，为阵发性夜间血红蛋白尿和非典型溶血性尿毒症综合征这两种与成人和儿童肾脏和血管功能紊乱有关的疾病带来了创新的治疗选择。
The company is pushing forward the therapy's approval for other new indications and the approval for another medicine to treat a rare neurofibroma, a neurological condition, to benefit more patients, said Hu.
胡说，该公司正在推进该疗法对其他新适应症的批准，以及对另一种治疗罕见神经纤维瘤（一种神经疾病）的药物的批准，以使更多患者受益。
The US Food and Drug Administration announced earlier this week that it had approved a medicine from Luye Pharma Group for the treatment of schizophrenia in adults and as monotherapy or adjunctive therapy for the maintenance treatment of bipolar I disorder in adults.
美国食品和药物管理局本周早些时候宣布，已批准鹿野制药集团的一种药物用于治疗成人精神分裂症，并作为成人双相情感障碍维持治疗的单一疗法或辅助疗法。
The division also received milestone payments via its cell and gene therapy (C>) and chemoproteomics platforms.
该部门还通过其细胞和基因治疗（C>）以及化学蛋白质组学平台获得了里程碑式的付款。
Over the past four years, several innovative products that Fosun Pharma had exhibited at the CIIE - they include cutting-edge medical devices like the da Vinci Surgical robot, a magnetic resonance guided radiation therapy system, and the CAR-T cell therapy - have gone on to enter the Chinese market.
在过去的四年里，复星医药在进博会上展出的几款创新产品——包括达芬奇手术机器人、磁共振引导放射治疗系统和CAR-T细胞疗法等尖端医疗设备——已经进入中国市场。
The therapy can provide lasting protection for a wide range of people with poor immunity and who are not fully protected by COVID-19 vaccines, and for those who are at high risk of virus exposure.
该疗法可以为免疫力差、没有得到新冠肺炎疫苗充分保护的人群以及病毒暴露风险高的人群提供持久保护。
The company said their upscale devices use technologies such as micro-vibration massage, radio-frequency heating, infrared and near-infrared light therapy and electrical muscle stimulation.
该公司表示，他们的高端设备使用了微振动按摩、射频加热、红外和近红外光治疗以及肌肉电刺激等技术。
Chinese biotech enterprise BeiGene announced on Monday that its cancer treatment Brukinsa (zanubrutinib) has been approved by authorities in Kuwait, Bahrain and Qatar for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
中国生物技术企业百济基因周一宣布，其癌症治疗药物Brukinsa（zanubrutinib）已获得科威特、巴林和卡塔尔当局的批准，用于治疗至少接受过一次治疗的成年套细胞淋巴瘤患者。
This latest therapy is designed to tackle resistance occurrence in routine treatment.
这种最新的治疗方法旨在解决常规治疗中出现的耐药性。
This is a clear demonstration of the company's robust global clinical development capabilities, and the next step is to expedite the therapy's simultaneous global development, said CEO Chris Lu.
首席执行官Chris Lu表示，这清楚地表明了该公司强大的全球临床开发能力，下一步是加快该疗法的全球同步开发。
As Pfizer's innovative targeted lung cancer therapy, the tablet demonstrates breakthrough in improving patients' progression-free survival, can better penetrate blood-brain barrier, and have less drug resistance, said the company.
辉瑞公司表示，作为其创新的靶向性癌症治疗方案，该片在提高患者无进展生存率方面取得了突破，可以更好地穿透血脑屏障，并减少耐药性。
It is recommended by the latest global guidelines as a preferred first-line therapy, and is expected to reshape the treatment landscape of the disease by providing patients with long-term benefits, the company said.
该公司表示，最新的全球指南建议将其作为首选一线疗法，并有望通过为患者提供长期益处来重塑该疾病的治疗格局。
"This innovative therapy is a great example of how Pfizer fulfills its mission to deliver 'breakthroughs that change patients' lives'," said Jean-Christophe Pointeau, president of Pfizer Biopharmaceuticals China.
辉瑞生物制药中国区总裁Jean-Christophe Pointeau表示：“这种创新疗法是一个很好的例子，说明辉瑞如何履行其使命，实现‘改变患者生活的突破’。”。
"Also, surufatinib is so far the only small-molecule targeted therapy that addresses all NET patients regardless of the origin of the tumor, and we believe that this drug will benefit many patients," he said.
他说：“此外，苏鲁法替尼是迄今为止唯一一种针对所有NET患者的小分子靶向治疗方法，无论肿瘤的起源如何，我们相信这种药物将使许多患者受益。”。
We've already begun the process to align our global systems, processes, and capabilities to offer world-class solutions to customers working on all bioproduction platforms, including monoclonal antibodies, cell and gene therapies, and mRNA, and supports both therapy and vaccine manufacturing including COVID-19 in China," Wang added.
王补充道：“我们已经开始调整我们的全球系统、流程和能力，为在所有生物生产平台上工作的客户提供世界级的解决方案，包括单克隆抗体、细胞和基因疗法以及mRNA，并支持治疗和疫苗生产，包括中国的新冠肺炎。”。
"We have worked closely with COVID-19 vaccine and therapy developers in China and prioritized supplies of mission-critical process chemicals, raw materials and single use consumables going into research and development as well as manufacturing to enable the faster development and supply of COVID-19 vaccines and therapies to patients in China and globally," Rapolu said.
拉波卢说：“我们与中国的新冠肺炎疫苗和疗法开发商密切合作，优先供应用于研发和制造的关键任务工艺化学品、原材料和一次性消耗品，以加快新冠肺炎疫苗和疗法的开发和供应，造福中国和全球患者。”。
The meeting reported a series of newest breakthroughs in chimeric antigen receptor T-cell therapy.
会议报告了嵌合抗原受体T细胞治疗的一系列最新突破。
The five-year follow-up data updates of the single-arm phase II ZUMA-1 trial showed that the five-year overall survival rate was 42.6 percent among patients that have received CAR-T cell therapy.
单臂II期ZUMA-1试验的五年随访数据更新显示，接受CAR-T细胞治疗的患者的五年总生存率为42.6%。
In recent years, CAR-T cell therapy has achieved great success in the field of lymphoma.
近年来，CAR-T细胞治疗在淋巴瘤领域取得了巨大成功。
Many studies have indicated that CAR-T therapy and hematopoietic stem-cell transplantation have a complementary effect when used together, and can achieve better efficacy.
许多研究表明，CAR-T疗法与造血干细胞移植联合使用具有互补作用，可以获得更好的疗效。
For example, patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have achieved better survival benefits after receiving ASCT combined with CAR-T therapy.
例如，复发/难治性弥漫性大B细胞淋巴瘤（R/R-DLBCL）患者在接受ASCT联合CAR-T治疗后，获得了更好的生存益处。
What benefits will be achieved with the combination of ASCT and CAR-T therapy?
ASCT和CAR-T疗法的结合会带来什么好处？
ASCT is currently a critical treatment for lymphoma, but what would the efficacy be if it is combined with the promising CAR-T therapy?
ASCT目前是淋巴瘤的关键治疗方法，但如果它与有前景的CAR-T疗法相结合，疗效会如何？
Professor Zhou Jianfeng, director of the Department of Hematology at Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, together with his team members, has applied the innovative combination of traditional autologous hematopoietic stem-cell transplantation with CAR-T therapy to the treatment of relapsed and refractory lymphoma.
华中科技大学同济医学院同济医院血液科主任周剑锋教授携团队成员，将传统自体造血干细胞移植与CAR-T疗法的创新结合应用于复发难治性淋巴瘤的治疗。
The results of this groundbreaking clinical study were published last August in the core global hematology journal "Transplantation and Cellular Therapy".
这项开创性的临床研究结果于去年8月发表在全球血液学核心期刊《移植与细胞治疗》上。
Case sharing: Combination of ASCT and CAR-T therapy improves CNS lymphoma patient survival benefitsOn Dec 21, Wu, a 52 years old woman, who suffered from DLBCL with multiple parts of the brain affected, received autologous hematopoietic stem-cell transplantation combined with CAR-T therapy at Tongji Hospital of Huazhong University of Science and Technology.
案例分享：ASCT和CAR-T联合治疗提高中枢神经系统淋巴瘤患者生存率12月21日，吴，一名52岁的女性，患有DLBCL，大脑多个部位受到影响，在华中科技大学同济医院接受了自体造血干细胞移植和CAR-T联合治疗。
Chief physician Meng Fankai, a member of the Tongji CAR-T therapy team, said, "As a typical case of lymphoma involving the central nervous system, Wu received six cycles of chemotherapy in the local hospital and developed memory impairment.
同济CAR-T治疗团队成员孟凡凯主任医师说：“作为中枢神经系统淋巴瘤的典型病例，吴在当地医院接受了六个周期的化疗，并出现了记忆障碍。
"After a detailed evaluation, the team from the Department of Hematology of Tongji Hospital decided to adopt autologous hematopoietic stem-cell transplantation combined with CAR-T therapy for Wu.
“经过详细评估，同济医院血液科团队决定对吴采用自体造血干细胞移植结合CAR-T治疗。
With large-scale promotion and application of this therapy in the future, it will be possible to offer new options to save patients suffering from lymphoma.
随着这种疗法在未来的大规模推广和应用，将有可能为挽救淋巴瘤患者提供新的选择。
With proper and personalized pretreatment for tumor reduction and effective control of the disease in the CNS, patients with CNS involvement are no longer problem in CAR T-cell therapy.
通过适当和个性化的肿瘤减少预处理和中枢神经系统疾病的有效控制，中枢神经系统受累的患者在CAR T细胞治疗中不再是问题。
Moreover, autologous transplantation combined with CAR T-cell therapy has a high complete remission rate, and the depth of remission is better than that of CAR T-cell therapy alone.
此外，自体移植联合CAR T细胞治疗具有较高的完全缓解率，且缓解深度优于单独CAR T淋巴细胞治疗。
After receiving autologous transplantation combined with CAR-T therapy, patients with CNS involvement may overcome adverse prognostic factors and achieve good efficacy.
接受自体移植联合CAR-T治疗后，中枢神经系统受累患者可以克服不良预后因素，取得良好疗效。
The therapy, which was approved by the FDA on Friday, was a breakthrough after years of research and will bring novel treatment solutions for patients, especially those with drug-resistant or refractory conditions and those prone to develop into severe cases.
该疗法于周五获得美国食品药品监督管理局的批准，是经过多年研究后的一项突破，将为患者带来新的治疗方案，尤其是那些具有耐药性或难治性疾病的患者以及那些容易发展为重症的患者。
"With an estimated 200,000 patients living with the disease in China, we see a great need to bring the therapy to Chinese patients with this autoimmune disease as expeditiously as possible," said Samantha Du, founder, chairwoman and CEO of Zai Lab.
Zai Labs创始人、董事长兼首席执行官Samantha Du表示：“中国估计有20万名患者患有这种疾病，我们认为非常有必要尽快将这种疗法带给患有这种自身免疫性疾病的中国患者。”。
The drug has the potential to be the first-of-its-kind therapy in this disease area in China," Du said.
该药物有可能成为中国首个在该疾病领域进行此类治疗的药物，”杜说。
Zai Lab said it has also initiated Phase II confirmatory research for multiple new indications of the drug in China to accelerate the development of more autoimmune indications for the therapy on a global scale.
Zai Lab表示，它还在中国启动了该药物多种新适应症的II期验证研究，以加快在全球范围内开发更多的自身免疫适应症。
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond COVID-19.
该协议标志着百度利用其在计算生物学方面的优势，在新冠肺炎之后的现实世界制药实践中优化mRNA疫苗和治疗设计，这是一个里程碑。
Since 2011, the US company has completed close to 30 transactions in China, and would continue to deploy capital in digitalization, molecular diagnostics, bioprocessing and bioproduction to help pharmaceutical and biopharmaceutical companies discover, develop and manufacture drugs, and gene and cell therapy to provide individualized therapeutic treatment in an efficient way.
自2011年以来，这家美国公司已在中国完成了近30笔交易，并将继续在数字化、分子诊断、生物加工和生物生产方面部署资金，帮助制药和生物制药公司发现、开发和制造药物，以及基因和细胞治疗，以高效的方式提供个性化治疗。
"The innovative therapy can significantly lower the recurrence rate of inflammatory diseases.
“创新疗法可以显著降低炎症性疾病的复发率。
One is an allogeneic stem cell therapy used to treat complex perianal fistulas in Crohn's disease, and the other is an injection used to treat patients with short bowel syndrome who are dependent on parenteral support.
一种是异基因干细胞疗法，用于治疗克罗恩病的复杂肛周瘘，另一种是用于治疗依赖肠外支持的短肠综合征患者的注射。
The company's immune checkpoint LAG-3 Relatlimab, a cancer therapy, made its China debut at the CIIE.
该公司的免疫检查点LAG-3 Relatlimab是一种癌症疗法，在中国首次亮相CIIE。
The therapy is the company's third checkpoint inhibitor following the PD-1 inhibitor and CTLA-4 inhibitor.
该疗法是该公司继PD-1抑制剂和CTLA-4抑制剂之后的第三种检查点抑制剂。
Zhang said that pacing therapy is the only effective treatment for bradycardia, and that innovative, leadless pacing devices help patients avoid problems such as complications during surgery, inconvenience to mobility and high postoperative infection risk that come with traditional pacing therapy.
张说，起搏治疗是治疗心动过缓的唯一有效方法，创新的无引线起搏设备有助于患者避免传统起搏治疗带来的手术并发症、行动不便和术后感染风险高等问题。
In fiscal 2021, the figures for the US cancer therapy specialist Varian, which was acquired in April, were included for the first time.
2021财年，4月份收购的美国癌症治疗专家瓦里安的数据首次被包括在内。
British pharmaceutical company GlaxoSmithKline said that an innovative therapy to treat chronic obstructive pulmonary disease, which only needs to be taken once daily, attracted attention from medical circles and visitors during the 2019 CIIE, and was listed on the NRDL the following year.
Another CIIE spillover effect experienced by the company was the approval of its therapy for juvenile systemic lupus erythematosus.
In the CAR-T academic session on Oct 16, international experts and scholars gave presentations and exchanged views on the role of CAR-T cell therapy in hematological tumors.
Professor Zhao Weili from Ruijin Hospital of the Shanghai Jiao Tong University School of Medicine made a closing speech and shared the Chinese experience with CAR-T therapy.
Zhao discussed the treatment of two diffuse large B-cell lymphoma patients in China who received CAR-T cell therapy.
For instance, at last year's CIIE, the company debuted a water vapor therapy as a minimally invasive treatment for benign prostatic hyperplasia.
"China was the world's second market to have the hypertension indication for this therapy.
Swiss dermatology company Galderma, which will debut at this year's China International Import Expo, said it will introduce another nine medical beauty products, six skin care products, and a dermatitis therapy to the China market by 2024.
Some products that have not entered the China market or are still in the research and development phase, including a liquid botulinum toxin and a medical therapy to treat atopic dermatitis, will also be exhibited.
The application was granted priority review status and a breakthrough therapy designation by the country's drug review authority, according to the company.
"There is no therapy for drug-resistant CML patients in the domestic market so far.
It was granted priority review status and a breakthrough therapy designation by the country's drug review authority, the company said.
A new application for the drug has also been submitted in China and it was granted priority review status and a breakthrough therapy designation by the country's drug review authority, according to the company.
"There is no similar therapy in the domestic market so far.
At the fair in Beijing, the company will ink strategic collaborations with different players in the health sector, including a precise testing provider, and insurance companies, to prepare to help patients use the right therapy, improve drug accessibility, and ease patients' financial burden after the drug candidate's market approval, which may be expected in the fourth quarter of this year.
Besides South Korea, the company also submitted new drug approvals of the therapy in five other markets - the Chinese mainland, Australia, Singapore, and China's Hong Kong and Taiwan – over the past eight months.
As a vast geographic area with a combined population of 6.5 billion, the emerging markets region presents significant growth opportunities in unmet patient needs across key therapy areas.
Shan said the company will seek partnerships to work on new projects in cutting-edge technological fields including AI, machine learning and smart devices, with focus on disease screenings, diagnosis solutions, combining drugs and digital therapy solutions, data analytics and infrastructure.